Year |
Citation |
Score |
2019 |
Stefanick JF, Omstead DT, Ashley JD, Deak PE, Mustafaoglu N, Kiziltepe T, Bilgicer B. Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31473250 DOI: 10.1016/J.Jconrel.2019.08.033 |
0.624 |
|
2016 |
Ashley JD, Quinlan CJ, Schroeder VA, Suckow MA, Pizzuti VJ, Kiziltepe T, Bilgicer B. Dual Carfilzomib and Doxorubicin Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma. Molecular Cancer Therapeutics. PMID 27196779 DOI: 10.1158/1535-7163.Mct-15-0867 |
0.483 |
|
2014 |
Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Alves NJ, Suzuki R, Kikuchi S, Hideshima T, Anderson KC, Kiziltepe T, Bilgicer B. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. Journal of Controlled Release : Official Journal of the Controlled Release Society. 196: 113-21. PMID 25312543 DOI: 10.1016/J.Jconrel.2014.10.005 |
0.526 |
|
2014 |
Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Kiziltepe T, Bilgicer B. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. Journal of Medicinal Chemistry. 57: 5282-92. PMID 24897555 DOI: 10.1021/Jm500352V |
0.482 |
|
2014 |
Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends in Biotechnology. 32: 32-45. PMID 24210498 DOI: 10.1016/J.Tibtech.2013.09.007 |
0.478 |
|
2014 |
Stefanick J, Ashley J, Kiziltepe T, Bilgicer B. Abstract 5376: Systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomal nanoparticles Cancer Research. 74: 5376-5376. DOI: 10.1158/1538-7445.Am2014-5376 |
0.575 |
|
2013 |
Stefanick JF, Ashley JD, Bilgicer B. Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. Acs Nano. 7: 8115-27. PMID 24003770 DOI: 10.1021/Nn4033954 |
0.534 |
|
2013 |
Alves NJ, Cusick W, Stefanick JF, Ashley JD, Handlogten MW, Bilgicer B. Functionalized liposome purification via Liposome Extruder Purification (LEP). The Analyst. 138: 4746-51. PMID 23841107 DOI: 10.1039/C3An00680H |
0.618 |
|
2013 |
Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. Acs Nano. 7: 2935-47. PMID 23421406 DOI: 10.1021/Nn305663E |
0.549 |
|
2013 |
Kiziltepe T, Ashley J, Stefanick J, Bilgicer B. Abstract 4524: Designer nanoparticles for selective targeting of multiple myeloma and overcoming CAM-DR. Cancer Research. 73: 4524-4524. DOI: 10.1158/1538-7445.Am2013-4524 |
0.589 |
|
2013 |
Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. A systematic analysis of peptide linker length and polyethylene glycol coating on cellular uptake of peptide-targeted liposomes Pharmaceutical Discovery, Development and Manufacturing Forum 2013 - Core Programming Area At the 2013 Aiche Annual Meeting: Global Challenges For Engineering a Sustainable Future. 221-222. |
0.338 |
|
2012 |
Alves NJ, Stimple SD, Handlogten MW, Ashley JD, Kiziltepe T, Bilgicer B. Small-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targeting. Analytical Chemistry. 84: 7721-8. PMID 22928545 DOI: 10.1021/Ac300952R |
0.597 |
|
2012 |
Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA, Navari RM, Bilgicer B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer Journal. 2: e64. PMID 22829966 DOI: 10.1038/Bcj.2012.10 |
0.663 |
|
2012 |
Kiziltepe T, Ashley JD, Stefanick JF, Alves NJ, Handlogten MW, Qi YM, Suckow M, Navari R, Bilgicer B. Abstract 5686: Engineering multifunctional nanoparticles to selectively target multiple myeloma cells and overcome cell adhesion-mediated drug resistance Cancer Research. 72: 5686-5686. DOI: 10.1158/1538-7445.Am2012-5686 |
0.581 |
|
2011 |
Bilgicer B, Kiziltepe T, Ashley J, Qi YM, Stefanick J. Abstract 3636: Enhancement of trastuzumab selectivity via cyclic complex formation Cancer Research. 71: 3636-3636. DOI: 10.1158/1538-7445.Am2011-3636 |
0.43 |
|
Show low-probability matches. |